Tempus AI, Inc. (TEM) – What Are Researchers Thinking About This Stock?

Shares of Tempus AI, Inc. (NASDAQ:TEM) have received a consensus rating of “Hold” from the twenty-two analysts that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $72.37.

A number of research firms have recently issued reports on TEM. Stifel Nicolaus reduced their target price on Tempus AI from $60.00 to $50.00 and set a “hold” rating for the company in a report on Monday, August 3rd. TD Cowen reissued a “buy” rating on shares of Tempus AI in a research report on Wednesday, July 15th. Canaccord Genuity Group increased their price objective on Tempus AI from $80.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, October 12th. Wall Street Zen upgraded Tempus AI from a “sell” rating to a “hold” rating in a report on Saturday, July 25th. Finally, Guggenheim boosted their price objective on shares of Tempus AI from $65.00 to $92.00 and gave the company a “buy” rating in a research report on Thursday, October 1st.

Tempus AI Trading Down 9.0%

Shares of TEM opened at $64.72 on Monday. The business’s 50-day moving average price is $68.07 and its 200 day moving average price is $56.49. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06. The stock has a market capitalization of $11.68 billion, a P/E ratio of -44.94 and a beta of 3.54. Tempus AI has a 1-year low of $40.77 and a 1-year high of $96.29.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. The company had revenue of $382.49 million during the quarter, compared to analyst estimates of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The business’s quarterly revenue was up 21.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.22) earnings per share. Analysts expect that Tempus AI will post -1.38 earnings per share for the current year.

Insider Activity at Tempus AI

In other news, EVP Andrew Polovin sold 2,951 shares of Tempus AI stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $75.00, for a total transaction of $221,325.00. Following the completion of the sale, the executive vice president directly owned 135,189 shares in the company, valued at $10,139,175. The trade was a 2.14% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nadja West sold 3,000 shares of Tempus AI stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $69.00, for a total value of $207,000.00. Following the sale, the director owned 31,981 shares of the company’s stock, valued at approximately $2,206,689. This represents a 8.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 1,280,965 shares of company stock worth $80,397,564. 24.26% of the stock is currently owned by company insiders.

Institutional Trading of Tempus AI

Several large investors have recently added to or reduced their stakes in TEM. Eagle Health Investments LP acquired a new stake in shares of Tempus AI in the first quarter worth $11,588,000. Aristotle Atlantic Partners LLC bought a new position in Tempus AI during the first quarter worth $6,179,000. Headlands Technologies LLC bought a new position in Tempus AI during the second quarter worth $2,689,000. Odyssean LLC bought a new position in Tempus AI during the second quarter worth $897,000. Finally, Virtu Financial LLC raised its stake in Tempus AI by 384.6% during the 4th quarter. Virtu Financial LLC now owns 54,797 shares of the company’s stock valued at $3,236,000 after purchasing an additional 43,490 shares during the last quarter. 24.22% of the stock is owned by institutional investors.

Tempus AI Company Profile

Tempus AI, Inc is a technology company focused on applying artificial intelligence and data analytics to precision medicine. The company develops tools intended to help physicians make more informed treatment decisions by combining clinical information, molecular data and other health-related datasets.

Tempus provides genomic testing and diagnostic services, including sequencing and other molecular tests used primarily in oncology. Its platform also offers data and software solutions designed to support clinical research, pharmaceutical development, patient identification for clinical trials and the development of personalized treatment strategies.

Founded in 2015, Tempus is headquartered in Chicago and primarily serves healthcare providers, researchers and life sciences companies.